Alimera Sciences, Inc.
NASDAQ: ALIM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Richard S. Eiswirth Jr.
- Employees
- 154
- Headquarters
- Alpharetta, United States
- IPO year
- 2019
- Market cap
- $301.3M
- Website
- https://alimerasciences.com
Loading ALIM…
Loading profile data…Frequently asked questions about ALIM
What does Alimera Sciences, Inc. (ALIM) do?
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision...
Where does ALIM trade?
Alimera Sciences, Inc. (ALIM) trades on the NASDAQ Global Market.
What sector is ALIM in?
Alimera Sciences, Inc. (ALIM) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Alimera Sciences, Inc.?
Richard S. Eiswirth Jr. is the chief executive officer of Alimera Sciences, Inc. (ALIM).
Where is Alimera Sciences, Inc. headquartered?
Alimera Sciences, Inc. is headquartered in United States.
Does ALIM pay a dividend?
Alimera Sciences, Inc. (ALIM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALIM go public?
Alimera Sciences, Inc. (ALIM) completed its initial public offering in 2019.